Search research articles
Contact Us
Filters
Showing results (1-10 of 185) with videos related to
Page
of 19
Sort By:
Seminars in Oncology
|
August 5, 2010
The evolving role of bone-conserving therapy in patients with breast cancer
Adam M Brufsky
Breast Cancer : Basic and Clinical Research
|
August 16, 2014
Current Approaches and Emerging Directions in HER2-resistant Breast Cancer
Adam M Brufsky
Expert Opinion on Pharmacotherapy
|
April 2, 2008
Zoledronic acid for cancer therapy--induced and postmenopausal bone loss
Adam M Brufsky
Clinical Medicine Insights. Oncology
|
January 22, 2016
Delaying Chemotherapy in the Treatment of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
Adam M Brufsky
Clinical Breast Cancer
|
February 20, 2008
Managing bone loss in women with early-stage breast cancer receiving aromatase inhibitors
Adam M Brufsky
Current Oncology Reports
|
March 28, 2008
Bone health issues in women with early-stage breast cancer receiving aromatase inhibitors
Adam M Brufsky
The Breast Journal
|
May 28, 2014
Managing postmenopausal women with hormone receptor-positive advanced breast cancer who progress on endocrine therapies with inhibitors of the PI3K pathway
Adam M Brufsky
Oncology (Williston Park, N.Y.)
|
July 17, 2015
Some Excitement, Some Disappointment
Adam M Brufsky
Cancer Treatment Reviews
|
July 19, 2017
Long-term management of patients with hormone receptor-positive metastatic breast cancer: Concepts for sequential and combination endocrine-based therapies
Adam M Brufsky
The Oncologist
|
February 29, 2008
Cancer treatment-induced bone loss: pathophysiology and clinical perspectives
Adam M Brufsky
Page
of 19
Search research articles
Search
Showing results (1-10 of 185) with videos related to
Sort By:
Page
of 19
Seminars in Oncology
|
August 5, 2010
The evolving role of bone-conserving therapy in patients with breast cancer
Adam M Brufsky
Breast Cancer : Basic and Clinical Research
|
August 16, 2014
Current Approaches and Emerging Directions in HER2-resistant Breast Cancer
Adam M Brufsky
Expert Opinion on Pharmacotherapy
|
April 2, 2008
Zoledronic acid for cancer therapy--induced and postmenopausal bone loss
Adam M Brufsky
Clinical Medicine Insights. Oncology
|
January 22, 2016
Delaying Chemotherapy in the Treatment of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
Adam M Brufsky
Clinical Breast Cancer
|
February 20, 2008
Managing bone loss in women with early-stage breast cancer receiving aromatase inhibitors
Adam M Brufsky
Current Oncology Reports
|
March 28, 2008
Bone health issues in women with early-stage breast cancer receiving aromatase inhibitors
Adam M Brufsky
The Breast Journal
|
May 28, 2014
Managing postmenopausal women with hormone receptor-positive advanced breast cancer who progress on endocrine therapies with inhibitors of the PI3K pathway
Adam M Brufsky
Oncology (Williston Park, N.Y.)
|
July 17, 2015
Some Excitement, Some Disappointment
Adam M Brufsky
Cancer Treatment Reviews
|
July 19, 2017
Long-term management of patients with hormone receptor-positive metastatic breast cancer: Concepts for sequential and combination endocrine-based therapies
Adam M Brufsky
The Oncologist
|
February 29, 2008
Cancer treatment-induced bone loss: pathophysiology and clinical perspectives
Adam M Brufsky
Page
of 19